219 related articles for article (PubMed ID: 26789997)
21. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy.
Baron-Bodo V; Batard T; Nguyen H; Fréreux M; Horiot S; Harwanegg C; Bergmann KC; de Beaumont O; Moingeon P
Clin Exp Allergy; 2012 Oct; 42(10):1510-8. PubMed ID: 22994348
[TBL] [Abstract][Full Text] [Related]
22. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
23. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.
Eifan AO; Akkoc T; Yildiz A; Keles S; Ozdemir C; Bahceciler NN; Barlan IB
Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188
[TBL] [Abstract][Full Text] [Related]
24. The IgE Blocking Activity Induced by Dermatophagoides pteronyssinus Subcutaneous Immunotherapy Does Not Correlate with Specific IgA but with IgG4 in both Serum and Saliva.
He Y; Liu J; Zhao D; Zhang S; Hao G; Sun Y; Zhong H; Chen H; Würtzen PA; Larsen JN; Lai X
Int Arch Allergy Immunol; 2021; 182(12):1231-1244. PubMed ID: 34280916
[TBL] [Abstract][Full Text] [Related]
25. House dust mite sublingual immunotherapy: results of a US trial.
Bush RK; Swenson C; Fahlberg B; Evans MD; Esch R; Morris M; Busse WW
J Allergy Clin Immunol; 2011 Apr; 127(4):974-81.e1-7. PubMed ID: 21333346
[TBL] [Abstract][Full Text] [Related]
26. Immunologic alterations and efficacy of subcutaneous immunotherapy with Dermatophagoides pteronyssinus in monosensitized and polysensitized patients.
Soyyigit S; Guloglu D; Ikinciogullari A; Secil D; Oztuna D; Mungan D; Misirligil Z; Sin BA
Ann Allergy Asthma Immunol; 2016 Mar; 116(3):244-251.e2. PubMed ID: 26945497
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of D. pteronyssinus immunotherapy in local allergic rhinitis: a double-blind placebo-controlled clinical trial.
Rondón C; Campo P; Salas M; Aranda A; Molina A; González M; Galindo L; Mayorga C; Torres MJ; Blanca M
Allergy; 2016 Jul; 71(7):1057-61. PubMed ID: 27008542
[TBL] [Abstract][Full Text] [Related]
28. Safety profile and immunological response of dual sublingual immunotherapy with house dust mite tablet and Japanese cedar pollen tablet.
Gotoh M; Okubo K; Yuta A; Ogawa Y; Nagakura H; Ueyama S; Ueyama T; Kawashima K; Yamamoto M; Fujieda S; Sakashita M; Sakamoto H; Iwasaki N; Mori E; Endo T; Ohta N; Kitazawa H; Okano M; Asako M; Takada M; Terada T; Inaka Y; Yonekura S; Matsuoka T; Kaneko S; Hata H; Hijikata N; Tanaka H; Masuyama K; Okamoto Y
Allergol Int; 2020 Jan; 69(1):104-110. PubMed ID: 31421989
[TBL] [Abstract][Full Text] [Related]
29. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.
Mosbech H; Deckelmann R; de Blay F; Pastorello EA; Trebas-Pietras E; Andres LP; Malcus I; Ljørring C; Canonica GW
J Allergy Clin Immunol; 2014 Sep; 134(3):568-575.e7. PubMed ID: 24797423
[TBL] [Abstract][Full Text] [Related]
30. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial.
Demoly P; Corren J; Creticos P; De Blay F; Gevaert P; Hellings P; Kowal K; Le Gall M; Nenasheva N; Passalacqua G; Pfaar O; Tortajada-Girbés M; Vidal C; Worm M; Casale TB
J Allergy Clin Immunol; 2021 Mar; 147(3):1020-1030.e10. PubMed ID: 32890575
[TBL] [Abstract][Full Text] [Related]
31. SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis.
Klimek L; Mosbech H; Zieglmayer P; Rehm D; Stage BS; Demoly P
Expert Rev Clin Immunol; 2016; 12(4):369-77. PubMed ID: 26788764
[TBL] [Abstract][Full Text] [Related]
32. Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial.
Wang DH; Chen L; Cheng L; Li KN; Yuan H; Lu JH; Li H
Laryngoscope; 2013 Jun; 123(6):1334-40. PubMed ID: 23616386
[TBL] [Abstract][Full Text] [Related]
33. Semi-depot house-dust mite allergen extract for Chinese with allergic rhinitis and asthma.
Li X; Wang X; Lin X; Xu G; Tao Z; Jiang W; Cheng L; Guo Y; Lai H; Shen K
Am J Rhinol Allergy; 2016 May; 30(3):201-8. PubMed ID: 27216351
[TBL] [Abstract][Full Text] [Related]
34. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
[TBL] [Abstract][Full Text] [Related]
35. Early Intervention Improves Clinical Responses to House Dust Mite Immunotherapy in Allergic Rhinitis Patients.
Qi S; Chen H; Huang N; Li W; Liu G; Wang Y; Hu L; Wang X; Zhang W; Zhu R
Int Arch Allergy Immunol; 2016; 171(3-4):234-240. PubMed ID: 28049194
[TBL] [Abstract][Full Text] [Related]
36. Clinical and immunologic effects of sublingual immunotherapy on patients with allergic rhinitis to house-dust mites: 1-year follow-up results.
Kim ST; Han DH; Moon IJ; Lee CH; Min YG; Rhee CS
Am J Rhinol Allergy; 2010; 24(4):271-5. PubMed ID: 20819465
[TBL] [Abstract][Full Text] [Related]
37. In-vivo allergenic potency of Siriraj Mite Allergen Vaccine (SMAV) comparing with standardized vaccine in mite-sensitive patients.
Visitsunthorn N; Bunnag C; Pacharn P; Assanasen P; Jirapongsananuruk O; Thongngarm T; Tantilipikorn P; Vichyanond P
Asian Pac J Allergy Immunol; 2011 Mar; 29(1):50-6. PubMed ID: 21560488
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of subcutaneous house dust mite immunotherapy in patients with moderate to severe allergic rhinitis.
Valero A; Ibáñez-Echevarría E; Vidal C; Raducan I; Castelló Carrascosa JV; Sánchez-López J
Immunotherapy; 2022 Jun; 14(9):683-694. PubMed ID: 35465692
[TBL] [Abstract][Full Text] [Related]
39. Regulation of constitutive neutrophil apoptosis due to house dust mite allergen in normal and allergic rhinitis subjects.
Kim EH; Lee JS; Lee NR; Baek SY; Kim EJ; Lee SJ; Kim IS
PLoS One; 2014; 9(9):e105814. PubMed ID: 25243400
[TBL] [Abstract][Full Text] [Related]
40. 300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis.
Demoly P; Okamoto Y; Yang WH; Devillier P; Bergmann KC
Expert Rev Clin Immunol; 2016 Nov; 12(11):1141-1151. PubMed ID: 27632814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
